Region USA

Chiesi USA Sales reached €258 million, representing

overall growth of 2.6%.

2017 was a year of challenges and, ultimately, a year of success for Chiesi USA. Multiple product approvals were achieved. These included approval for the completed tech transfer for Retavase® and two new strengths for Pertzye®, 4,000 and 24,000. 2017 was also the first full year of our Corporate Social Responsibility program, Chiesi in the Community.

Ken McBean

General Manager Chiesi USA, Inc.


The main achievement for Chiesi USA was exceeded budget on both revenue and profitability, after adjusting for the generic competition for ZyfloCR.

Chiesi in the Community was also a major success. The program had a positive impact beyond expectations on affiliate awareness, positive impact in the local community and company culture.